aTyr Pharma Announces Poster Presentation at ASCO-SITC Clinical Immuno-Oncology Symposium
- Abstract Title: Identification of Novel Liquid Biopsy Biomarker for Monitoring the
Immune Set Pointin Both Solid Tumor and Hematological Malignancy Patients
- Author: David King, Ph.D., aTyr
Pharma, Inc., San Diego, CA
- Location: San Francisco Marriott Marquis,
San Francisco, CA
ORCA is a preclinical research program that targets a novel, proprietary immuno-oncology pathway using antibodies to change levels of extracellular histidyl-tRNA synthetase (HARS), known as the Resokine pathway, in tumor settings. aTyr believes tumors, across multiple tumor types, utilize the Resokine pathway to evade immune system responses. aTyr has evaluated the therapeutic potential of targeting this novel pathway in multiple in-vitro and in-vivo tumor models, in comparison to and in combination with incumbent check-point modulators. Based on the tumor model data, the company believes that targeting this pathway may reduce or, in some cases, reverse tumor growth either as a monotherapy or in combination therapy.
This press release contains forward-looking statements within the meaning of the Private Litigation Reform Act. Forward-looking statements are usually identified by the use of words such as “anticipates,” “believes,” “estimates,” “expects,” “intends,” “may,” “plans,” “projects,” “seeks,” “should,” “will,” and variations of such words or similar expressions. We intend these forward-looking statements to be covered by such safe harbor provisions for forward-looking statements and are making this statement for purposes of complying with those safe harbor provisions. These forward-looking statements, including statements regarding the potential and potential therapeutic benefits of ATYR1940 (Resolaris), ATYR1923 (iMod.Fc), or potential product candidates from our ORCA program, the ability of the Company to successfully advance our pipeline or product candidates, undertake certain development activities (such as clinical trial enrollment and the conduct of clinical trials) and accomplish certain development goals and the timing of such activities and development goals, the timing of our clinical trials, our ability to receive regulatory approvals for, and commercialize, our product candidates and of reporting results from our clinical trials, and the scope and strength of our intellectual property portfolio, reflect our current views about our plans, intentions, expectations, strategies and prospects, which are based on the information currently available to us and on assumptions we have made. Although we believe that our plans, intentions, expectations, strategies and prospects as reflected in or suggested by those forward-looking statements are reasonable, we can give no assurance that the plans, intentions, expectations or strategies will be attained or achieved. Furthermore, actual results may differ materially from those described in the forward-looking statements and will be affected by a variety of risks and factors that are beyond our control including, without limitation, risks associated with the discovery, development and regulation of our Physiocrine-based product candidates, the risk that we may cease or delay preclinical or clinical development activities for any of its existing or future product candidates for a variety of reasons (including difficulties or delays in patient enrollment in planned clinical trials), and the risk that we may not be able to raise the additional funding required for our business and product development plans, as well as those set forth in our most recent Annual Report on Form 10-K for the year ended
|Sr. Director, Investor Relations|
Source: aTyr Pharma, Inc.